XML 23 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Cash flows from operating activities:      
Net income (loss) $ (8,049,815) $ (1,003,938) $ 671,108
Adjustments to reconcile net income (loss) to net cash flows provided by (used in) operating activities:      
Depreciation and amortization expense 2,647,753 2,396,908 2,246,809
Deferred tax expense 4,206,753 619,580 490,227
Share-based compensation 1,115,063 852,102 622,503
Share-based compensation (foundation contribution) 372,500 0 0
Excess tax (benefit) expense derived from exercise of stock options (91,109) 1,026,413 (90,982)
Noncash interest expense 77,911 84,539 46,422
Noncash investment gains (52,012) (74,015) (77,155)
Net changes in assets and liabilities affecting operating activities:      
Accounts receivable (1,064,985) (1,253,007) (572,392)
Inventories (1,366,118) (1,101,586) 1,330,176
Prepaid, other current assets and other assets (1,074,369) (1,556,282) (263,084)
Accounts payable and other current liabilities 2,307,617 191,901 1,475,964
Other long-term liabilities 413,097 386,863 (2,731)
Net cash provided by (used in) operating activities (557,714) 569,478 5,876,865
Cash flows from investing activities:      
Additions to property and equipment (275,960) (130,872) (142,965)
Additions to intangible assets (1,213,110) (2,000,226) (2,556,465)
Proceeds from sale of marketable securities 13,381,061 4,489,111 7,883,171
Purchases of marketable securities (2,379,414) (5,473,092) (7,528,713)
Net cash provided by (used in) investing activities 9,512,577 (3,115,079) (2,344,972)
Cash flows from financing activities:      
Borrowings on line of credit 24,500,000 2,400,000 1,700,000
Repayments on line of credit (18,800,000) 0 0
Repurchase of common shares (3,724,375) (2,520,715) (5,338,967)
Payments of deferred equity offering costs (27,950) 0 0
Cash settlement of contingent consideration 0 0 (1,668,252)
Exercise of stock options 0 0 21,366
Excess tax (expense) benefit derived from exercise of stock options 0 (1,026,413) 90,982
Net cash provided by (used in) financing activities 1,947,675 (1,147,128) (5,194,871)
Net increase (decrease) in cash and cash equivalents 10,902,538 (3,692,729) (1,662,978)
Cash and cash equivalents, beginning of year 34,510,330 38,203,059 39,866,037
Cash and cash equivalents, end of year 45,412,868 34,510,330 38,203,059
Net cash paid (refunded) during the year for:      
Interest 14,993 21,853 27,434
Income taxes 18,000 (8,359) 52,238
Noncash investing and financing activities:      
Change in unpaid invoices for purchases of intangibles (513,481) (1,179,394) 967,146
Deferred offering costs included in accounts payable and other accrued expenses $ 97,254 $ 0 $ 0